BRCA1 and ovarian carcinoma: Furthermore, results from the PRIMA/ENGOT-OV26/GOG-3012 trial demonstrated niraparib efficacy for BRCA1/2 wildtype patients and patients with intact homologous recombination repair in addition to efficacy for BRCA1/2 mutated and homologous recombination repair-deficient ovarian cancer patients [88].